GI
INMB icon

GAMMA Investing’s INmune Bio INMB Stock Holding History

GAMMA Investing’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.35K Sell
829
-775
-48% -$1.07K ﹤0.01% 3812
2026
Q1 		$1.81K Buy
1,604
+1,423
+786% +$2.03K ﹤0.01% 3691
2025
Q4 		$282 Buy
+181
New +$323 ﹤0.01% 3974
2025
Q2 		– Sell
-44
Closed -$344 – 3834
2025
Q1 		$344 Buy
+44
New +$349 ﹤0.01% 3726

Other funds holding INMB

CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return

GAMMA Investing's INMB Position: Q2 2026 in Review

GAMMA Investing reduced its INmune Bio (INMB) stake by 48% in Q2 2026, selling an estimated $1.07K and leaving 829 shares worth $1.35K. The position accounts for ﹤0.01% of the portfolio, ranked #3812.

GAMMA Investing first reported a position in INMB in Q1 2025 and has held it in 4 quarters since. The position peaked at $1.81K in Q1 2026. 8 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

  • GAMMA Investing held 829 shares of INmune Bio worth $1.35K as of Q2 2026.
  • GAMMA Investing sold 775 INmune Bio shares in Q2 2026, an estimated $1.07K.
  • INmune Bio made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3812 holding.
  • GAMMA Investing first reported a position in INmune Bio in Q1 2025 and has held it in 4 quarters since.
  • GAMMA Investing's INmune Bio position peaked at $1.81K in Q1 2026.
  • 8 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.